Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT06063668
Other study ID # Autotaxin in sle
Secondary ID
Status Not yet recruiting
Phase
First received
Last updated
Start date October 2023
Est. completion date October 2025

Study information

Verified date October 2023
Source Assiut University
Contact Mariam Mohamed Abd-Elrazik Ahmed, resident
Phone 01009979491
Email mariammoham36@gmail.com
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

- Estimation of the serum ATX level in SLE patients in comparison to healthy subjects. - Evaluation of the relation of serum ATX level with disease activity and different clinical manifestation in SLE patients


Description:

Systemic lupus erythematosus (SLE) is a chronic multisystem autoimmune inflammatory disease with unknown etiology . However, several genetic, immunological and environmental factors play a role in the etiopathogenesis of SLE . During the disease course, patients may be presented with diverse clinical manifestations (mucocutaneous, articular, neurological, or renal manifestations) . Anti-nuclear antibodies(ANA), anti- double stranded DNA (ds-DNA)and anti smith(SM) antibodies are common biomarkers of SLE. However the sensitivity and specificity of the current biomarkers are not ideal that the diagnosis of SLE can be missed . Lysophospholipids are phospholipids with only one fatty acid chain, such as lysophosphatidic acid (LPA) and lysophosphatidylserine. Autotaxin (ATX), one of the enzymes that catalyze the formation of Lysophospholipid, is mainly responsible for the production of LPA in blood . Tumor necrosis factor (TNF), interleukin-6 (IL-6), and type I interferons, have been reported to induce the expression of ATX . ATX was reported recently as potential biomarkers of various diseases (serum ATX in malignancy and chronic hepatitis C, while in acute myocardial infarction ATX was overexpressed in cardiac tissue and in the synovium of rheumatoid arthritis patients) . Several studies have reported that serum ATX concentrations were higher in females than in males . The mRNA expression of ATX was found to be significantly induced by estrogen . There is growing evidence that ATX may play a role in the pathogenesis of SLE. Few recent studies have reported that serum ATX level can be a possible novel biomarker and key molecule in SLE .


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 94
Est. completion date October 2025
Est. primary completion date October 2024
Accepts healthy volunteers
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria: - Patients who will be diagnosed as SLE according to the 2012 systemic lupus international collaborating clinics (SLICC) criteria . - SLE Patients older than 18 years old. Exclusion Criteria: - SLE Patients younger than 18 years old. - Patients with other rheumatic diseases or overlap syndromes. - Patients with malignancy. - Patients with chronic hepatitis C.

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Assiut University

References & Publications (13)

Cojocaru M, Cojocaru IM, Silosi I, Vrabie CD. Manifestations of systemic lupus erythematosus. Maedica (Bucur). 2011 Oct;6(4):330-6. — View Citation

Gladman DD, Ibanez D, Urowitz MB. Systemic lupus erythematosus disease activity index 2000. J Rheumatol. 2002 Feb;29(2):288-91. — View Citation

Iwata Y, Kitajima S, Yamahana J, Shimomura S, Yoneda-Nakagawa S, Sakai N, Furuichi K, Ogura H, Sato K, Toyama T, Yamamura Y, Miyagawa T, Hara A, Shimizu M, Ohkawa R, Kurano M, Yatomi Y, Wada T. Higher serum levels of autotaxin and phosphatidylserine-speci — View Citation

Magkrioti C, Galaris A, Kanellopoulou P, Stylianaki EA, Kaffe E, Aidinis V. Autotaxin and chronic inflammatory diseases. J Autoimmun. 2019 Nov;104:102327. doi: 10.1016/j.jaut.2019.102327. Epub 2019 Aug 28. — View Citation

Masuda A, Nakamura K, Izutsu K, Igarashi K, Ohkawa R, Jona M, Higashi K, Yokota H, Okudaira S, Kishimoto T, Watanabe T, Koike Y, Ikeda H, Kozai Y, Kurokawa M, Aoki J, Yatomi Y. Serum autotaxin measurement in haematological malignancies: a promising marker — View Citation

Petri M, Orbai AM, Alarcon GS, Gordon C, Merrill JT, Fortin PR, Bruce IN, Isenberg D, Wallace DJ, Nived O, Sturfelt G, Ramsey-Goldman R, Bae SC, Hanly JG, Sanchez-Guerrero J, Clarke A, Aranow C, Manzi S, Urowitz M, Gladman D, Kalunian K, Costner M, Werth — View Citation

Stoll T, Seifert B, Isenberg DA. SLICC/ACR Damage Index is valid, and renal and pulmonary organ scores are predictors of severe outcome in patients with systemic lupus erythematosus. Br J Rheumatol. 1996 Mar;35(3):248-54. doi: 10.1093/rheumatology/35.3.24 — View Citation

Tan EM. Antinuclear antibodies: diagnostic markers for autoimmune diseases and probes for cell biology. Adv Immunol. 1989;44:93-151. doi: 10.1016/s0065-2776(08)60641-0. No abstract available. — View Citation

Tokuhara Y, Kurano M, Shimamoto S, Igarashi K, Nojiri T, Kobayashi T, Masuda A, Ikeda H, Nagamatsu T, Fujii T, Aoki J, Yatomi Y. A New Enzyme Immunoassay for the Quantitative Determination of Classical Autotaxins (ATXalpha, ATXbeta, and ATXgamma) and Nove — View Citation

Tsuchida Y, Shoda H, Nakano M, Ota M, Okamura T, Yamamoto K, Kurano M, Yatomi Y, Fujio K, Sawada T. Autotaxin is a potential link between genetic risk factors and immunological disturbances of plasmacytoid dendritic cells in systematic lupus erythematosus — View Citation

Tsuchida Y, Shoda H, Sawada T, Fujio K. Role of autotaxin in systemic lupus erythematosus. Front Med (Lausanne). 2023 Apr 4;10:1166343. doi: 10.3389/fmed.2023.1166343. eCollection 2023. — View Citation

Yu H, Nagafuchi Y, Fujio K. Clinical and Immunological Biomarkers for Systemic Lupus Erythematosus. Biomolecules. 2021 Jun 22;11(7):928. doi: 10.3390/biom11070928. — View Citation

Zhang G, Cheng Y, Zhang Q, Li X, Zhou J, Wang J, Wei L. ATX-LPA axis facilitates estrogen-induced endometrial cancer cell proliferation via MAPK/ERK signaling pathway. Mol Med Rep. 2018 Mar;17(3):4245-4252. doi: 10.3892/mmr.2018.8392. Epub 2018 Jan 8. — View Citation

* Note: There are 13 references in allClick here to view all references

Outcome

Type Measure Description Time frame Safety issue
Primary Serum ATX level in SLE patients in comparison to healthy controls. Measure ATX level in serum of sle patients and compare it with ATX level in serum of healthy controls. 2 years
See also
  Status Clinical Trial Phase
Completed NCT05624437 - BElimumab corticoSteroids Sparing Treatment in Systemic Lupus Erythematosus
Recruiting NCT06445127 - Evaluation of Patients With Lupus Nephritis Using Kidney MRI (Magnetic Resonance Imaging) N/A
Recruiting NCT04866615 - Posterior Segment Evaluation of Patients With SLE Using OCT and OCTA
Not yet recruiting NCT04645225 - Clinical Characteristic and MEFV Gene Mutations in Patient With Juvenile Onest Systemic Lupus Erythematosus
Recruiting NCT04604990 - National Systemic Lupus Erythematosus Prospective Cohort, Saudi Arabia
Recruiting NCT06150651 - Safety of PiggyBac Transposon CAR T-cells Targeting CD-19 in Refractory Lupus. Phase 1
Recruiting NCT06056921 - Safety and Efficacy of CD19 Targeted CAR-T Therapy for Refractory Autoimmune Disease Phase 1
Recruiting NCT06294236 - Study Evaluating SC291 in Subjects With Severe r/r B-cell Mediated Autoimmune Diseases (GLEAM) Phase 1
Recruiting NCT05866861 - A Study in Participants With Mild-to-moderate Systemic Lupus Erythematosus Phase 1